BioSpace News Archive

AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of immunological diseases with high unmet medical needs, today announced positive topline data from its Phase 1 trial evaluating the company’s subcutaneously administered immune checkpoint enhancer (ICE), ALTB-268 in healthy volunteers.

LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, announced the launch of its Early Lung Cancer Center.

Coeptis Therapeutics Holdings, Inc. announced that it has submitted a 513(g) request to the U.S. Food and Drug Administration (FDA) for an in vitro companion diagnostic test designed to be used with anti-CD38 monoclonal antibody therapies.

Biosero, Inc., developer of laboratory automation solutions to orchestrate scientific discoveries, today announced the promotion of Rob Harkness, PhD, to the position of Chief Technology Officer.

Foldax® , Inc., a leader in the development of innovative, polymer heart valves, today announced that the first 30 patients have been treated outside of the U.S., in the Indian clinical trial of the TRIA™ surgical mitral heart valve.

Anbio, a leading provider of innovative diagnostic solutions, made a successful market presence at the 2023 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo

Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced $20 million in Series A extension funding committed by Apple Tree Partners (ATP).

Recursion, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced its participation in the following investor conference.

Qualigen Therapeutics, Inc. announces today that the U.S. Food and Drug Administration (FDA) has cleared the Company’s IND application for QN-302, a potential best-in-class small molecule G-Quadruplex (G4)-selective transcription inhibitor.

FDA has approved Harm Reduction Therapeutics’ (HRT) new drug application for RiVive™ (Naloxone HCl Nasal Spray 3 mg) to be available over the counter (OTC) for the emergency treatment of opioid overdose.